By
Drug Target Review2024-12-12T08:00:03
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T11:12:00Z
2023-07-11T16:13:06
Sponsored by Agilent
2024-02-06T08:57:06
Sponsored by bit.bio
2026-06-30T14:00:00
Sponsored by Analytik Jena GmbH + Co. KG
2026-10-28T14:00:00
Sponsored by Miltenyi Biotec
2023-02-07T15:25:20
Sponsored by Bio-Techne
2026-03-25T15:00:00
Sponsored by Yokogawa
Site powered by Webvision Cloud